June 18, 2024

Asthma Therapeutics Market Size to Hit USD 45.28 Bn by 2033

The global asthma therapeutics market size surpassed USD 26.84 billion in 2023 and is expected to grow around USD 45.28 billion by 2033 with a CAGR of 5.37% from 2024 to 2033.

Asthma Therapeutics Market Size 2024 to 2033

Key Points

  • North America dominated the market with the largest market share of 51% in 2023.
  • Asia Pacific is observed to witness the fastest rate of growth during the forecast period.
  • By drug class, the anti-inflammatory segment has contributed the largest market share of 63% in 2023.
  • By drug class, the combination therapy segment is observed to witness a notable rate of growth during the forecast period.
  • By product, the inhalers segment dominated the market in 2023.
  • By route of administration, the inhaled segment recorded more than 47% of revenue share in 2023.

The Asthma Therapeutics Market is a dynamic sector within the pharmaceutical industry, primarily focused on addressing the challenges posed by asthma, a chronic respiratory condition characterized by inflammation and narrowing of the airways. As one of the most prevalent respiratory disorders globally, the market for asthma therapeutics plays a crucial role in improving the quality of life for millions of individuals affected by this condition. This market encompasses a diverse range of pharmaceutical products and treatment approaches aimed at managing and alleviating asthma symptoms.

Get a Sample: https://www.precedenceresearch.com/sample/3875

Growth Factors

Several key growth factors contribute to the expansion of the Asthma Therapeutics Market. Technological advancements in drug development and delivery systems have led to the introduction of innovative and more effective asthma medications. Additionally, a growing awareness of asthma-related health issues, coupled with an increase in healthcare expenditure, has fueled market growth. The rising prevalence of asthma across different age groups and demographic segments has heightened the demand for advanced therapeutics, driving the pharmaceutical industry’s investment in asthma-related research and development.

Asthma Therapeutics Market Scope

Report CoverageDetails
Growth Rate from 2024 to 2033CAGR of 5.37%
Global Market Size in 2023USD 26.84 Billion
Global Market Size by 2033USD 45.28 Billion
U.S. Market Size in 2023USD 9.58 Billion
U.S. Market Size by 2033USD 16.16 Billion
Base Year2023
Forecast Period2024 to 2033
Segments CoveredBy Drug Class, By Product, and By Route of Administration
Regions CoveredNorth America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Asthma Therapeutics Market Dynamics


The Asthma Therapeutics Market is driven by various factors that influence both demand and supply dynamics. Increased air pollution, changing lifestyles, and a rise in environmental triggers contribute to the growing incidence of asthma, creating a sustained demand for effective therapeutics. Furthermore, supportive government initiatives and healthcare policies aimed at improving respiratory health contribute to market growth. The expansion of distribution channels, coupled with strategic collaborations between pharmaceutical companies, enhances the accessibility of asthma medications, thereby driving market demand.


Amid the challenges, the Asthma Therapeutics Market presents promising opportunities for pharmaceutical companies. The exploration of biologics and personalized medicine holds significant potential for tailoring asthma treatments to individual patient profiles. Additionally, the integration of digital health technologies in asthma management, such as smart inhalers and telemedicine solutions, opens new avenues for patient engagement and real-time monitoring. Emerging markets with a growing healthcare infrastructure present untapped opportunities for market players to expand their reach and cater to the rising demand for asthma therapeutics.


Despite the positive growth trajectory, the Asthma Therapeutics Market faces several challenges. Patent expirations and generic competition pose threats to the revenue streams of established asthma medications. Adherence issues among patients, driven by factors such as complex treatment regimens and medication costs, remain a challenge for healthcare providers. Moreover, the variability in treatment responses among individuals and the need for personalized medicine present hurdles in the development of universally effective asthma therapeutics.


The regional landscape significantly influences the Asthma Therapeutics Market. Developed regions, such as North America and Europe, have well-established healthcare infrastructures and high awareness levels, driving market growth. In these regions, a strong emphasis on research and development activities fosters innovation in asthma therapeutics. On the other hand, developing regions in Asia-Pacific, Latin America, and Africa present unique opportunities for market expansion, with increasing healthcare investments and a rising prevalence of asthma.

Read Also: UV LED Market Size to Touch USD 4,436.57 Million by 2033

Recent Developments

  • In August 2023, The Phase II EXHALE-1 research results for dexpramipexole have been posted online in the Journal of Clinical Immunology and Allergy (JACI), according to a statement from Areteia Therapeutics, Inc. In individuals with eosinophilic asthma, the study aimed to assess the safety and effectiveness of dexpramipexole in reducing blood and airway eosinophilia.
  • In January 2023, The European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) gave AstraZeneca’s Tezspire a reasonable opinion for self-administration in pre-filled, single-use pens for patients with severe asthma who are 12 years of age and older. The very nature of the Type-II label variant allows for implementing the CHMP opinion without requiring a decision by the European Commission.

Key Market Players

  • Teva Pharmaceutical Industries Ltd.
  • GSK plc
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • Sanofi.
  • Koninklijke Philips N.V.
  • BD
  • Covis Pha

Segments Covered in the Report

By Drug Class

  • Anti- inflammatory
  • Bronchodilators
  • Combination Therapy

By Product

  • Inhalers
    • Dry Powder
    • Metered Dose
    • Soft Mist
  • Nebulizers

By Route of Administration

  • Oral
  • Inhaled
  • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.expresswebwire.com/

Blog: https://www.uswebwire.com/

Blog: https://www.dailytechbulletin.com/

Blog: https://www.autoindustrybulletin.com/